Compare · BSX vs PRCT
BSX vs PRCT
Side-by-side comparison of Boston Scientific Corporation (BSX) and PROCEPT BioRobotics Corporation (PRCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and PRCT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 61.5x PRCT ($1.04B).
- PRCT has been more active in the news (6 items in the past 4 weeks vs 5 for BSX).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- PROCEPT BioRobotics Corporation
- Price
- -
- -
- Market cap
- $63.97B
- $1.04B
- 1M return
- +1.88%
- -
- 1Y return
- -55.28%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 6
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest PRCT
- PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
- Barclays initiated coverage on PROCEPT BioRobotics with a new price target
- SEC Form 4 filed by PROCEPT BioRobotics Corporation
- SEC Form 3 filed by PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- EVP, CLO, CORP. SEC. Nouri Alaleh sold $6,223 worth of shares (297 units at $20.95), decreasing direct ownership by 0.23% to 127,737 units (SEC Form 4) to cover withholding tax
- EVP, Chief Technology Officer Templin Barry L sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.39% to 94,826 units (SEC Form 4) to cover withholding tax
- EVP, CFO Waters Kevin sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.21% to 180,355 units (SEC Form 4) to satisfy withholding tax
- PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026